Alliances
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.
Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.
Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
PRESS RELEASES